Potassium Citrate
- Atc Codes:A12BA02
- CAS Codes:6100-05-6#866-84-2
- PHARMGKB ID:6100-05-6#866-84-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Poland: Kalium Granulat Bezcukrowy, Litocid; Spain: Acalka, Uralyt-Urato; Sweden: Kajos; UK: Potassium Citrate Mixture.
North America
Canada: K-Citra, K-Lyte, Polycitra-K; USA: Urocit-K.
Latin America
Argentina: LTK250, Urokit Casasco; Brazil: Litocit.
Asia
Japan: Pinaloc, Potorend, Toronorm, Uralyt, Urinmet, Uroacis, Utagen.
Drug combinations
Potassium Citrate and Potassium Bicarbonate
Other Potassium Citrate Combinations: Calcium Citrate
Chemistry
Potassium Citrate: C~6~H~5~K~3~O~7~ H~2~O. Mw: 324.41. (1) 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, tripotassium salt, monohydrate; (2) Tripotassium citrate monohydrate. CAS-6100-05-6; CAS-866-84-2 (anhydrous).
Pharmacologic Category
Replacement Preparations; Potassium Supplements. Alkalinizing Agent. (ATC-Code: A12BA02).
Mechanism of action
Therapeutic use
Prevention of uric acid nephrolithiasis. Prevention of calcium renal stones in hypocitraturia. Urinary alkalinizer when sodium citrate contraindicated.
Pregnancy and lactiation implications
Compatible with breast-feeding.
Unlabeled use
Contraindications
Severe renal insufficiency. Sodium-restricted diet (sodium citrate). Untreated Addison’s disease. Severe myocardial damage. Acute dehydration. Hyperkalemia. Delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or patients taking anticholinergic medication. Active urinary tract infection.
Warnings and precautions
May cause gastrointestinal upset and lead to gastrointestinal ulceration, bleeding, perforation and/or obstruction. Oral liquid preparations (not solid) should be used in esophageal compression or delayed gastric emptying. Severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (e.g. heart block, ventricular arrhythmias, asystole). Changes in serum potassium concentrations can occur during acid/base correction (use with caution in acid/base alterations). Patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia (use with caution in cardiovascular disease (e.g. heart failure, cardiac arrhythmias)). Conversion of citrate to bicarbonate in liver may be blocked in hepatic failure, and in patients who are severely ill or in shock. Use with caution in disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (e.g. untreated Addison’s disease, heat cramps, severe tissue breakdown from trauma or burns). Use with caution in renal impairment (contraindicated with severe impairment), in digitalized patients (may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations), and in patients receiving concomitant medications or therapies which increase potassium (e.g. ACEI, potassium-sparing diuretics, potassium-containing salt substitutes).